| 000 | 03183nas a22002777a 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20230504114906.0 | ||
| 006 | m|||||r|||| 00| 0 | ||
| 007 | ta | ||
| 008 | 171219t2020 sp ||||| |||| 00| 0 spa | | ||
| 022 | _a0007-0912 | ||
| 040 | _cSalus Infirmorum | ||
| 245 | 0 | 0 |
_aRandomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery /
_cBrandon M. Togioka, David Yanez, Michael F. Aziz, Janna R. Higgins, Praveen Tekkali and Miriam M. Treggiari |
| 300 | _a448kb | ||
| 504 | _aBibliografía: p.560-561 | ||
| 520 | 8 | _aBackground: Residual neuromuscular block has been associated with postoperative pulmonary complications. We hypothesised that sugammadex reduces postoperative pulmonary complications in patients aged �70 yr having surgery�3 h, compared with neostigmine. Methods: Patients were enrolled in an open-label, assessor-blinded, randomised, controlled trial. At surgical closure, subjects were equally randomised to receive sugammadex 2 mg kg�1 or neostigmine 0.07 mg kg�1 (maximum 5 mg) for rocuronium reversal. The primary endpoint was incidence of postoperative pulmonary complications. Secondary end-points included residual paralysis (train-of-four ratio <0.9 in the PACU) and Phase 1 recovery (time to attain pain control and stable respiratory, haemodynamic, and neurological status). The analysis was by intention-to-treat. Results: Of the 200 subjects randomised, 98 received sugammadex and 99 received neostigmine. There was no significant difference in the primary endpoint of postoperative pulmonary complications despite a signal towards reduced incidence for sugammadex (33% vs 40%; odds ratio [OR]¼0.74; 95% confidence interval [CI]¼[0.40, 1.37]; P¼0.30) compared with neostigmine. Sugammadex decreased residual neuromuscular block (10% vs 49%; OR¼0.11, 95% CI¼[0.04, 0.25]; P<0.001). Phase 1 recovery time was comparable between sugammadex (97.3 min [standard deviation, SD¼54.3]) and neostigmine (110.0 min [SD¼62.0]), difference e12.7 min (95% CI, [e29.2, 3.9], P¼0.13). In an exploratory analysis, there were fewer 30 day hospital readmissions in the sugammadex group compared with the neostigmine group (5% vs 15%; OR¼0.30, 95% CI¼[0.08, 0.91]; P¼0.03). Conclusions: In older adults undergoing prolonged surgery, sugammadex was associated with a 40% reduction in re-sidual neuromuscular block, a 10% reduction in 30 day hospital readmission rate, but no difference in the occurrence ofpostoperative pulmonary complications. Based on this exploratory study, larger studies should determine whether sugammadex may reduce postoperative pulmonary complications and 30 day hospital readmissions. Clinical trial registration: NCT02861131. | |
| 653 | 1 | 4 | _aacetylcholinesterase inhibitor |
| 653 | 1 | 4 | _acyclodextrin |
| 653 | 1 | 4 | _aneostigmine |
| 653 | 1 | 4 | _aneuromuscular block |
| 653 | 1 | 4 | _apulmonary complications |
| 653 | 1 | 4 | _arocuronium |
| 653 | 1 | 4 | _asugammadex |
| 773 |
_g-- 2020 v. 124, n.5, p.553-561 _tBritish Journal of Anaesthesia |
||
| 942 |
_2udc _cARTÍCULO |
||
| 999 |
_c15051 _d15051 |
||